FilingSEC EDGAR8-K
Atossa Therapeutics Approves CVR Issuance Plan for Priority Review Voucher Proceeds
· SEC accepted
StagePlanning
Filing content
Atossa Therapeutics approved a plan to issue contingent value rights (CVRs) to share a portion of net proceeds from a potential rare pediatric disease priority review voucher with shareholders.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…